Bakteriofagi i fagoterapia

• Autorzy: Gryko R , Parasion S. , Mizak L.

Warianty tytułu

EN

Bacteriophages and phage therapy

• Języki publikacji: PL

Abstrakty

EN

The article presents the biology of bacteriophages and their diagnostic and therapeutic applications, including recombinants with the use of the phage display method. Clinical efficacy of phage therapy, especially in cases of antibiotic-resistant infections, including those complicated by MRSA strains, are underlined. The article also discusses the results of experimental studies, which can provide directions for future investigations and therapeutic applications of bacteriophages.

Słowa kluczowe

PL

bakteriofagi; infekcja fagowa; receptory fagowe; terapia fagowa

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2010
• Tom: 66
• Numer: 04
• Strony: 232-235
• Opis fizyczny: s.232-235,bibliogr.

Twórcy

autor

Gryko R

• Wojskowy Instytut Higieny i Epidemiologii, ul.Lubelska 2, 24-100 Pulawy

autor

Parasion S.

autor

Mizak L.

Bibliografia

• 1.Barrow O., Lovell M., Berchieri A. jr.: Use of Lytic Bacteriophage for Control of Experimental Escherichia coli Septicemia and Meningitis in Chicken and Calves. Clin. Diagn. Lab. Immunol. 1998, 5, 294.
• 2.Biswas B., Adhya S., Washart P., Paul B., Trostel A. N., Powell B., Carlton R., Merril C. R.: Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin resistant Enterococcus faecium. Infect. Immun. 2002, 70, 204-210.
• 3.Borysowski J., Górski A.: Is phage therapy acceptable in the immunocompromised host?. Int. J. Infect. Dis. 2008, 12, 466-471.
• 4.Borysowski J., Górski A.: Zastosowanie metody phage display w eksperymentalnej terapii onkologicznej. Postepy Hig. Med. Dośw. 2004, 58, 100-107.
• 5.Cairns B. J., Payne R. J. H.: Bacteriophage Therapy and the Mutant Selection Window. Antimicrob. Agents Chemother. 2008, 52, 4344-4350.
• 6.Capparelli R., Parlato M., Borriello G., Salvatore P., Iannelli D.: Experimental Phage Therapy against Staphylococcus aureus in Mice. Antimicrob. Agents Chemother. 2007, 51, 2765-2773.
• 7.Clark J. R., March J. B.: Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnology. 2006, 24, 212-218.
• 8.Dąbrowska K., Świtala-Jeleń K., Weber-Dąbrowska B., Górski A.: Bacteriophage penetration in vertebrates. J. Appl. Microbiol. 2005, 98, 7-13.
• 9.Dzuliashvili M., Gabitashvili K., Golidjashvili A., Hoyle N., Gachechiladze K.: Study of therapeutic potential of the experimental pseudomonas bacteriophage preparation. Georgian Med. News. 2007, 147, 81-88.
• 10.Górski A., Weber-Bą browska B., Międzybrodzki R., Fortuna W., Hanecki R.: Perspektywy terapii fagowej w urologii. Przegl. Urol. 2004, 4/5, 8-10.
• 11.Hanlon G. W.: Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int. J. Antimicrobial Agents. 2007, 30, 118-128.
• 12.Hermoso J. A., Garcɩa J. L., Garcɩa P.: Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr. Op. Microbiol. 2007, 10, 1-12.
• 13.Kropinski A. M.: Phage therapy - Everything old is new again. Can. J. Infect. Dis. Med. Microbiol. 2006, 17, 297-306.
• 14.Kutateladze M., Adamia R.: Phage therapy experience at the Eliava Institute. Med. Maladies Infect. 2008, 38, 426-430.
• 15.Levin B. R., Bull J. J.: Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2004, 2, 166-173.
• 16.Loc Carrillo C., Atterbury R. J., El-Shibiny A., Connerton P. L., Dillon E., Scott A., Connerton I. F.: Bacteriophage Therapy To Reduce Campylobacter jejuni Colonization of Broiler Chickens. Appl. Envir. Microbiol. 2005, 71, 6554-6563.
• 17.Matsuzaki S., Yasuda M., Nishikawa H., Kuroda M., Ujihara T., Shuin T., Shen Y., Jin Z., Fujimoto S., Nasimuzzaman M. D., Wakiguchi H., Shigeyoshi S., Sugiura T., Koda S., Muraoka A., Imai S.: Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage FMR11. J. Inf. Dis. 2003, 187, 613-624.
• 18.McVay C. S., Velásquez M., Fralick J. A.: Phage Therapy of Pseudomonas aeruginosa Infection in a Mouse Burn Wound Model. Antimicrob. Agents Chemother. 2007, 51, 1934-1938.
• 19.Międzybrodzki J., Małachowa N., Markiewski T., Białecka A., Kasprowicz A.: Różnicowanie izolatów Staphylococcus aureus w oparciu o cechy fenotypowe. Post. Hig. Med. Dośw. 2008, 62, 322-327.
• 20.Międzybrodzki R., Fortuna W., Weber-Dąbrowska B., Górski A.: Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Post. Hig. Med. Dośw. 2007, 61, 461-465.
• 21.Mushtaq N., Redpath M. B., Luzio J. P., Taylor P. W.: Treatment of experimental Escherichia coli infection with recombinant bacteriophage-derived capsule depolymerase. J. Antimicrob. Chemother. 2005, 56, 160-165.
• 22.O'Flynn G., Ross R. P., Fitzgerald G. F., Coffey A.: Evaluation of a Cocktail of Three Bacteriophages for Biocontrol of Escherichia coli O157:H7. Appl. Envir. Microbiol. 2004, 70, 3417-3424.
• 23.Parisen A., Allain B., Zhang J., Mandeville R., Lan C. Q.: Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J. Appl. Microbiol. 2008, 104, 1-13.
• 24.Pirisi A.: Phage therapy - advantages over antibiotics? Lancet 2000, 356, 1418.
• 25.Raya R. R., Varey P., Oot R. A., Dyen M. R., Callaway T. R., Edrington T. S., Kutter E. M., Brabban A. D.: Isolation and characterization of a new T-even bacteriophage, CEV1, and determination of its potential to reduce Escherichia coli O157:H7 levels in sheep. Appl. Environ. Microbiol. 2006, 72, 6405-6410.
• 26.Sheng H., Knecht H. J., Kudva I. T., Hovde C. J.: Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants. Appl. Envir. Microbiol. 2006, 72, 5359-5366.
• 27.Skurnik M., Strauch E.: Phage therapy: Facts and fiction. Int. J. Med. Microbiol. 2006, 296, 5-14.
• 28.Smith G. P., Petrenko V. A.: Phage display. Chem. Rev. 1997, 97, 391-410.
• 29.Vaca S., Arce J., Oliver G., Arenas D., Arguello F.: FIZ15 bacteriophage increases the adhesion of Pseudomonas aeruginosa to human buccal epithelial cells. Rev. Lat. Am. Microbiol. 1989, 31, 1-5.
• 30.Vinodkumar C. S., Kalsurmath S., Neelagund Y. F.: Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J. Path. Microbiol. 2008, 51, 360-366.
• 31.Wang J., Hu B., Xu M., Yan Q., Liu S., Zhu X., Sun Z., Reed E., Ding L., Gong J., Li Q. Q., Hu J.: Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int. J. Mol. Med. 2006, 17, 309-317.
• 32.Wang J., Hu B., Xu M., Yan Q., Liu S., Zhu X., Sun Z., Tao D., Ding L., Reed E., Gong J., Li Q. Q., Hu J.: Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia. Int. J. Mol. Med. 2006, 17, 347-355.
• 33.Weber-Dąbrowska B., Górski A., Zimecki M., Łusiak-Szelachowska M., Grzęda M., Lis M., Międzybrodzki R., Fortuna W., Dubiel A., Świtała-Jeleń K., Boratyński J.: Potencjalne możliwości wykorzystania bakteriofagów w leczeniu zakażeń bakteryjnych zwierząt. Medycyna Wet. 2006, 62, 1219-1221.
• 34.Westwater C., Kasman L. M., Schofield D. A., Werner P. A., Dolan J. W., Schmidt M. G., Norris J. S.: Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 2003, 47, 1301-1307.